Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01066208




Registration number
NCT01066208
Ethics application status
Date submitted
9/02/2010
Date registered
10/02/2010
Date last updated
19/08/2016

Titles & IDs
Public title
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Scientific title
ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Secondary ID [1] 0 0
ACREULAR001
Universal Trial Number (UTN)
Trial acronym
DCVAS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Wegener's Granulomatosis 0 0
Microscopic Polyangiitis 0 0
Churg Strauss Syndrome 0 0
Polyarteritis Nodosa 0 0
Giant Cell Arteritis 0 0
Takayasu Arteritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
WG classification - Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

MPA classification - Patients with microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

CSS classification - Patients with Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

PAN classification - Patients with polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

Control Classification - For each of the diseases being evaluated (WG, MPA, CSS, PAN, GCA, TAK), patients with the other 5 diseases will be the control group. Within these groups, 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

WG diagnostic - Patients with a new presentation of Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

MPA diagnostic - Patients with a new presentation of microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

CSS diagnostic - Patients with a new presentation of Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

PAN diagnostic - Patients with a new presentation of polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

Control diagnostic - Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

GCA classification - Patients with giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

TAK classification - Patients with Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.

GCA diagnostic - Patients with a new diagnosis of giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.

TAK diagnostic - Patients with a new diagnosis of Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Develop new diagnostic and classification criteria for ANCA associated vasculitis and polyarteritis nodosa
Timepoint [1] 0 0
3 years

Eligibility
Key inclusion criteria
Inclusion Criteria for Classification criteria:

1. Adult patients aged >18 years. There is no upper age limit.
2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
3. Presumed diagnosis of a primary systemic vasculitis.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria for classification criteria:

1. Patients < 18 years of age.
2. Inability to provide informed consent.
3. Hepatitis B or C
4. Co-morbidities that explain the clinical symptoms and signs on which the diagnosis of vasculitis is made. E.g. infection, tumour, other inflammatory condition, etc.

Inclusion criteria for diagnostic criteria:

1. Adult patients aged >18 years. There is no upper age limit.
2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
3. Suspected diagnosis of a primary systemic vasculitis

Inclusion criteria for controls group for diagnostic criteria:

1. Adult patients aged >18 years. There is no upper age limit.
2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
3. Patients presenting to secondary care with one of the following clinical presentations: I.Multi-system disease. Presentation of disease with at least 2 organs involved. II.Pulmonary-renal syndrome. Defined as haemoptysis / pulmonary haemorrhage with acute renal impairment. III.Acute renal failure IV.Acute respiratory distress. V.Chronic upper airways symptoms and signs. VI.Inflammatory polyarthritis. VII.Fever of unknown origin. VIII.Acute or chronic abdominal pain IX.Hypertension. X.Referred to secondary care with suspicion of vasculitis but confirmed not to have vasculitis. XII.New onset headache. XIII.Jaw or tongue pain. XIV.Sudden visual loss. XV.Limb claudication. XVI.Aortic aneurysm >5cm.

Exclusion Criteria for diagnostic criteria:

1. Patients under the age of 18
2. Patient or next of kin unable or unwilling to provide informed consent or assent.

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2018
Actual
Sample size
Target
3588
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,QLD
Recruitment hospital [1] 0 0
ANU Medical Centre - Canberra
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment postcode(s) [1] 0 0
- Canberra
Recruitment postcode(s) [2] 0 0
4029 - Herston
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
New Hampshire
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Utah
Country [13] 0 0
Argentina
State/province [13] 0 0
Catamarca
Country [14] 0 0
Argentina
State/province [14] 0 0
Buenos Aires
Country [15] 0 0
Austria
State/province [15] 0 0
Innsbruck
Country [16] 0 0
Belgium
State/province [16] 0 0
Leuven
Country [17] 0 0
Canada
State/province [17] 0 0
Manitoba
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec
Country [20] 0 0
Canada
State/province [20] 0 0
Calgary
Country [21] 0 0
China
State/province [21] 0 0
Beijing
Country [22] 0 0
Czech Republic
State/province [22] 0 0
Prague
Country [23] 0 0
Denmark
State/province [23] 0 0
Copenhagen
Country [24] 0 0
Egypt
State/province [24] 0 0
Assiut
Country [25] 0 0
Egypt
State/province [25] 0 0
Cairo
Country [26] 0 0
Finland
State/province [26] 0 0
Helsinki
Country [27] 0 0
France
State/province [27] 0 0
Paris
Country [28] 0 0
Germany
State/province [28] 0 0
Jena
Country [29] 0 0
Germany
State/province [29] 0 0
Luebeck
Country [30] 0 0
Germany
State/province [30] 0 0
Münster
Country [31] 0 0
Germany
State/province [31] 0 0
Plochingen
Country [32] 0 0
Germany
State/province [32] 0 0
Tübingen
Country [33] 0 0
Hungary
State/province [33] 0 0
Debrecen
Country [34] 0 0
India
State/province [34] 0 0
Uttar Pradesh
Country [35] 0 0
India
State/province [35] 0 0
Chandigarh
Country [36] 0 0
India
State/province [36] 0 0
Hyderabad
Country [37] 0 0
India
State/province [37] 0 0
New Delhi
Country [38] 0 0
India
State/province [38] 0 0
Vellore
Country [39] 0 0
Ireland
State/province [39] 0 0
Cork
Country [40] 0 0
Ireland
State/province [40] 0 0
Dublin 4
Country [41] 0 0
Italy
State/province [41] 0 0
Parma
Country [42] 0 0
Italy
State/province [42] 0 0
Reggio Emilia
Country [43] 0 0
Japan
State/province [43] 0 0
Chiba prefecture
Country [44] 0 0
Japan
State/province [44] 0 0
Ibaraki Prefecture
Country [45] 0 0
Japan
State/province [45] 0 0
Miyazaki Prefecture
Country [46] 0 0
Japan
State/province [46] 0 0
Saitama Prefecture
Country [47] 0 0
Japan
State/province [47] 0 0
Tokyo Prefecture
Country [48] 0 0
Japan
State/province [48] 0 0
Chiba
Country [49] 0 0
Japan
State/province [49] 0 0
Kagawa
Country [50] 0 0
Japan
State/province [50] 0 0
Kanagawa
Country [51] 0 0
Japan
State/province [51] 0 0
Kanazawa
Country [52] 0 0
Japan
State/province [52] 0 0
Okayama
Country [53] 0 0
Japan
State/province [53] 0 0
Osaka
Country [54] 0 0
Japan
State/province [54] 0 0
Saitama
Country [55] 0 0
Japan
State/province [55] 0 0
Tochigi-ken
Country [56] 0 0
Japan
State/province [56] 0 0
Tokyo
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Seoul
Country [58] 0 0
Mexico
State/province [58] 0 0
Mexico City
Country [59] 0 0
Netherlands
State/province [59] 0 0
Amsterdam
Country [60] 0 0
Netherlands
State/province [60] 0 0
Groningen
Country [61] 0 0
New Zealand
State/province [61] 0 0
Canterbury
Country [62] 0 0
New Zealand
State/province [62] 0 0
Auckland
Country [63] 0 0
New Zealand
State/province [63] 0 0
Hamilton
Country [64] 0 0
Norway
State/province [64] 0 0
Kristiansand
Country [65] 0 0
Norway
State/province [65] 0 0
Tromsø
Country [66] 0 0
Poland
State/province [66] 0 0
Kraków
Country [67] 0 0
Portugal
State/province [67] 0 0
Almada
Country [68] 0 0
Portugal
State/province [68] 0 0
Lisbon
Country [69] 0 0
Portugal
State/province [69] 0 0
Porto
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Moscow
Country [71] 0 0
Slovenia
State/province [71] 0 0
Ljubljana
Country [72] 0 0
Spain
State/province [72] 0 0
Catalonia
Country [73] 0 0
Sri Lanka
State/province [73] 0 0
Columbo 8
Country [74] 0 0
Sweden
State/province [74] 0 0
Lund
Country [75] 0 0
Sweden
State/province [75] 0 0
Stockholm
Country [76] 0 0
Sweden
State/province [76] 0 0
Umeå
Country [77] 0 0
Sweden
State/province [77] 0 0
Uppsala
Country [78] 0 0
Switzerland
State/province [78] 0 0
Basel
Country [79] 0 0
Switzerland
State/province [79] 0 0
Zurich
Country [80] 0 0
Turkey
State/province [80] 0 0
Ankara
Country [81] 0 0
Turkey
State/province [81] 0 0
Istanbul
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Cumbria
Country [83] 0 0
United Kingdom
State/province [83] 0 0
Essex
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Fife
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Scotland
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Suffolk
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Surrey
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Birmingham
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Cambridge
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Dudley
Country [91] 0 0
United Kingdom
State/province [91] 0 0
London
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Manchester
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Norwich
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Nottingham
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Oxford
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Reading
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Slough
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Southampton
Country [99] 0 0
United Kingdom
State/province [99] 0 0
York

Funding & Sponsors
Primary sponsor type
Other
Name
University of Oxford
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
American College of Rheumatology
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
The European League Against Rheumatism (EULAR)
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
The Vasculitis foundation
Address [3] 0 0
Country [3] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Raashid A Luqmani, DM, FRCP(E)
Address 0 0
University of Oxford, United Kingdom
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Raashid A Luqmani
Address 0 0
Country 0 0
Phone 0 0
+44 1865 738106
Fax 0 0
Email 0 0
raashid.luqmani@ndorms.ox.ac.uk
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01066208